Eric Becker, DO
Adult Medicine · Mobile, ALNPI 1720182447
Payments from drug & device makers
Across 474 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$985
- AbbVie$698
- Abbott$523
- Lilly USA, LLC$416
- Bayer$392
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,400100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 124 | $1,567 |
| AstraZeneca | 46 | $985 |
| AbbVie(2 entities) | 36 | $698 |
| Abbott | 27 | $523 |
| Lilly USA, LLC | 32 | $416 |
| Bayer | 23 | $392 |
| Johnson & Johnson | 24 | $323 |
| Boehringer Ingelheim | 19 | $291 |
| Novartis | 13 | $187 |
| Amgen | 16 | $186 |
| Pfizer | 12 | $169 |
| Merck | 11 | $160 |
| GSK | 9 | $153 |
| Sanofi-aventis U.S. LLC | 12 | $149 |
| Xeris Pharmaceuticals, Inc. | 7 | $148 |
| Corcept Therapeutics | 6 | $118 |
| Phathom Pharmaceuticals, Inc. | 5 | $89 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Sumitomo Pharma America, Inc. | 5 | $81 |
| Exact Sciences | 5 | $79 |
| Mannkind Corporation | 5 | $73 |
| Biohaven Pharmaceuticals, Inc. | 4 | $63 |
| Eisai Inc. | 5 | $61 |
| Mylan Specialty L.p. | 3 | $61 |
| GE HealthCare | 1 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Currax Pharmaceuticals LLC | 3 | $37 |
| Amarin Pharma, Inc. | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Vivus LLC | 2 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$116
How this compares
$7,408 in reported general payments places this provider in the 80th percentile of 26 adult medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 178 | $206,401 |
| OzempicSemaglutide | 87 | $136,626 |
| JardianceEmpagliflozin | 72 | $75,805 |
| JanuviaSitagliptin Phosphate | 68 | $73,590 |
| RybelsusSemaglutide | 56 | $55,528 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $43,743 |
| LinzessLinaclotide | 16 | $21,640 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $17,775 |
| VascepaIcosapent Ethyl | 24 | $17,763 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,029 |
| Atorvastatin Calcium | 664 | $7,037 |
| Amlodipine Besylate | 870 | $5,348 |
| Rosuvastatin Calcium | 341 | $5,239 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,495 |
| Losartan Potassium | 305 | $3,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $985 | $210,896190 claims |
| Novo NordiskOzempic, Rybelsus | $1,567 | $192,154143 claims |
| Boehringer IngelheimJardiance | $291 | $75,80572 claims |
| MerckJanuvia | $160 | $73,59068 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $153 | $61,51899 claims |
| AbbVieLinzess | $698 | $21,64016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 adult medicine providers in Alabama.
Other adult medicine in Mobile
- Eyston HunteMobile$139K
- Justin CulliferMobile$2K
- William SargeantMontgomery$1M
- Delano BenjaminForestdale$10K
- Walter BrandnerBirmingham$9K
- Jeremy LedfordOpelika$9K
- Anthony ChestangBirmingham$5K
- Jeremy AllenPell City$4K
- Adeel BodlaMadison$4K
- Yu-Yong Eugene TaiJasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.